Pursuant to Regulation 30 read with Clause 7 of Para A of Part A of Schedule Ill of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Abbott India has informed that Namita Shah - Associate Director - New Product Introduction and Therapy Area Strategy, has tendered her resignation from employment of the Company with effect from the close of business hours of April 15, 2025, to pursue opportunities outside the Company. Pursuant to her resignation, she will also cease to be the Senior Management Personnel of the Company effective the said date. The details required to be disclosed as per SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 is enclosed. Pursuant to Regulation 30 read with Clause 7C of Para A of Part A of Schedule Ill of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the letter of resignation of Namita Shah along with reasons shall be shared separately within seven days from the date the resignation comes into effect.
The above information is a part of company’s filings submitted to BSE.
